Literature DB >> 7688979

Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.

S Foulds1, C H Wakefield, M Giles, J Gillespie, J F Dye, P J Guillou.   

Abstract

mRNA for the suppressive epitope of p15E was found to be present in 24 of 30 samples of human colorectal cancer and in all four specimens of gastric cancer. mRNA for p15E was seldom seen in nonmalignant colonic or gastric mucosa but, when present, was associated with inflammatory or pre-malignant conditions of the digestive tract. Synthetic peptides derived from the conserved p15E sequence were found to suppress some aspects of the immune response implicated in anti-tumour activity. These data suggest that a p15E-related material with immunomodulatory properties is elaborated within human tumours, either by the tumour itself or as a normal component of the endogenous anti-tumour reaction.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7688979      PMCID： PMC1968406          DOI： 10.1038/bjc.1993.395

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  35 in total

1.  A role for endogenous retroviral sequences in the regulation of lymphocyte activation.

Authors:  A M Krieg; W C Gause; M F Gourley; A D Steinberg
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

Review 2.  The immunological status of the cancer patient.

Authors:  P J Guillou
Journal:  Curr Opin Immunol       Date:  1989-06       Impact factor: 7.486

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein.

Authors:  M Ogasawara; G J Cianciolo; R Snyderman; M Mitani; R A Good; N K Day
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

5.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Synthetic peptide homologous to the envelope proteins of retroviruses shares a cross-reacting epitope with the CD4 receptor.

Authors:  J Rothmann; N F Hassan; D E Campbell; N Kamani; S D Douglas
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

7.  Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products.

Authors:  M Nelson; D S Nelson; G J Cianciolo; R Snyderman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization.

Authors:  S Beissert; M Bergholz; I Waase; G Lepsien; A Schauer; K Pfizenmaier; M Krönke
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

9.  Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.

Authors:  J R Monson; C W Ramsden; G R Giles; T G Brennan; P J Guillou
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

10.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

Authors:  P J Guillou; C W Ramsden; S S Somers; P C Sedman
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640
View more
  8 in total

Review 1.  On viruses, sex, and motherhood.

Authors:  L P Villarreal; L P Villareal
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

2.  Surgical implications of tumour immunology.

Authors:  S S Somers
Journal:  Ann R Coll Surg Engl       Date:  1996-03       Impact factor: 1.891

Review 3.  Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease.

Authors:  H B Urnovitz; W H Murphy
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

4.  Glucocorticoid-mediated immunomodulation: hydrocortisone enhances immunosuppressive endogenous retroviral protein (p15E) expression in mouse immune cells.

Authors:  M Fiegl; E Strasser-Wozak; S Geley; A Gsur; J Drach; R Kofler
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth.

Authors:  M S Lang; E Hovenkamp; H F Savelkoul; P Knegt; W Van Ewijk
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

6.  In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy.

Authors:  Esther Giehl; Hiromichi Kosaka; Zuqiang Liu; Mathilde Feist; Udai S Kammula; Michael T Lotze; Congrong Ma; Zong Sheng Guo; David L Bartlett
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

7.  Anti-inflammatory and vasoprotective activity of a retroviral-derived peptide, homologous to human endogenous retroviruses: endothelial cell effects.

Authors:  George J Cianciolo; Salvatore V Pizzo
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.

Authors:  Min Yang; Esther Giehl; Chao Feng; Mathilde Feist; Hongqi Chen; Enyong Dai; Zuqiang Liu; Congrong Ma; Roshni Ravindranathan; David L Bartlett; Binfeng Lu; Zong Sheng Guo
Journal:  Cancer Immunol Immunother       Date:  2021-02-04       Impact factor: 6.968
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.